How To Guide Your Client's New Drug Past An FDA Quick Kill
Celgene Corp. took a hit last week when the company said the U.S. Food and Drug Administration wouldn't even consider its new drug application for its top-pipeline multiple sclerosis drug....To view the full article, register now.
Already a subscriber? Click here to view full article